Zhou Yinning, Ma Zhichao, Ai Ye
Pillar of Engineering Product Development, Singapore University of Technology and Design Singapore 487372 Singapore
RSC Adv. 2019 Oct 3;9(53):31186-31195. doi: 10.1039/c9ra01792e. eCollection 2019 Sep 26.
The ability to isolate rare circulating tumor cells (CTCs) from blood samples is essential to perform liquid biopsy as a routine diagnostic and prognostic test. Both label-free and surface biomarker-based cell sorting technologies have been developed to address the demand in high-integrity isolation of rare CTCs for cancer research. Label-free cell sorting mainly relies on the size difference between CTCs and blood cells; thus, it lacks sufficient sorting specificity. Surface biomarker-based cell sorting is highly specific; however, it requires expensive, labor-intensive, and time-consuming labeling due to the use of multiple sets of surface biomarkers. Because of the complex nature and high heterogeneity of tumorigenesis, it is difficult to rely on a single sorting process for high-integrity rare cell isolation. In this study, for the first time, we present a hybrid microfluidic cell sorting method combining high throughput size-dependent inertial focusing for size-based pre-enrichment and high accuracy fluorescence activated acoustic sorting for single cell isolation. After one single hybrid sorting process, we have demonstrated at least 2500-fold purity enrichment of MCF-7 breast cancer cells spiked in diluted whole blood samples with cell viability maintained at 91 ± 1% (viability before sorting was 94 ± 2%). This developed hybrid microfluidic cell sorting technique provides a promising solution for rare cell isolation needed in a variety of biological research and clinical applications.
从血液样本中分离罕见循环肿瘤细胞(CTC)的能力对于将液体活检作为常规诊断和预后测试至关重要。为满足癌症研究中对罕见CTC进行高完整性分离的需求,已开发出无标记和基于表面生物标志物的细胞分选技术。无标记细胞分选主要依赖于CTC与血细胞之间的大小差异;因此,它缺乏足够的分选特异性。基于表面生物标志物的细胞分选具有高度特异性;然而,由于使用多组表面生物标志物,它需要昂贵、费力且耗时的标记。由于肿瘤发生的复杂性质和高度异质性,很难依靠单一的分选过程来进行高完整性的罕见细胞分离。在本研究中,我们首次提出了一种混合微流控细胞分选方法,该方法结合了用于基于大小的预富集的高通量大小依赖性惯性聚焦和用于单细胞分离的高精度荧光激活声学分选。经过一次单一的混合分选过程,我们已证明在稀释的全血样本中加入的MCF-7乳腺癌细胞纯度富集了至少2500倍,细胞活力维持在91±1%(分选前活力为94±2%)。这种开发的混合微流控细胞分选技术为各种生物学研究和临床应用中所需的罕见细胞分离提供了一种有前景的解决方案。